Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Saved in:
| Title: | Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. |
|---|---|
| Authors: | Catto, J.W.F.1,2 (AUTHOR) j.catto@sheffield.ac.uk, Tran, B.3 (AUTHOR), Rouprêt, M.4 (AUTHOR), Gschwend, J.E.5 (AUTHOR), Loriot, Y.6 (AUTHOR), Nishiyama, H.7 (AUTHOR), Redorta, J.P.8 (AUTHOR), Daneshmand, S.9 (AUTHOR), Hussain, S.A.1,2 (AUTHOR), Cutuli, H.J.10 (AUTHOR), Procopio, G.11 (AUTHOR), Guadalupi, V.11 (AUTHOR), Vasdev, N.12,13 (AUTHOR), Naini, V.14 (AUTHOR), Crow, L.15 (AUTHOR), Triantos, S.15 (AUTHOR), Baig, M.15 (AUTHOR), Steinberg, G.16 (AUTHOR) |
| Source: | Annals of Oncology. Jan2024, Vol. 35 Issue 1, p98-106. 9p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.3116 |
